The Modernization of Cosmetics Regulation Act — MoCRA, passed in December 2022 — has moved from grace period to enforcement: cosmetic product facility registration and product listing with the FDA became required, with statutory enforcement beginning after the December 2024 deadlines and the FDA publishing its facility list in 2025. For label readers, the visible change ahead is fragrance allergen disclosure, which the law directs the FDA to standardize, with implementation expected in 2026-2027 as the rulemaking proceeds. This is the largest expansion of U.S. cosmetics oversight since 1938, per the FDA's own MoCRA pages.
Beauty Ring publishes information, not legal advice — compliance questions belong with a regulator or attorney; this article covers what the law changes for people who read labels.
What does MoCRA actually require?
Three things with consumer-facing consequences. Facilities making cosmetics must register with the FDA, and every product must be listed with its ingredients. Adverse-event reporting becomes mandatory — serious events must be reported to the FDA within 15 business days, per the statute. And safety substantiation is now required for every product, meaning a brand must hold evidence its formula is safe as used. What the law does not do: approve cosmetics pre-market, as the FDA does for drugs — the U.S. remains a post-market system, unlike the EU.
What changes for label readers?
Slowly, then noticeably. The ingredient-listing requirement means the FDA will hold a public record of what brands say is in their products — a cross-check that did not exist before, since an ingredient list previously sat on the package answerable to no registry. The detail other coverage skipped: MoCRA's fragrance provision requires the FDA to standardize disclosure of fragrance allergens, which EU shoppers already see and U.S. shoppers do not; the EU's 26-allergen list has been mandatory there since 2005 under EU Regulation 1223/2009. When the U.S. rule lands, sensitive consumers get the same named-allergen visibility on this side of the Atlantic.
What should readers do with this now?
Two habits translate immediately. If a brand's product is missing from the FDA's facility and listing system over time, that is a signal worth noting — small brands have scaled deadlines, but the registry gap will narrow. And for fragrance-sensitive readers, the current U.S. label's blanket "fragrance" ingredient remains legal until the allergen rule takes effect; the practical interim is brands that voluntarily disclose allergen breakdowns under EU-style practice.
What the statute establishes is a registration and reporting infrastructure U.S. cosmetics never had. What remains open is the allergen rulemaking's final text and dates — proposed, not yet in force, and no article can cite a deadline the FDA has not set.